Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Safety Study of Cobicistat-containing Antiretroviral Regimens in HIV-1 Patients with Mild to Moderate Renal Impairment
2011-000488-29Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cobicistat in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Estimated glomerular filtration rate (eGFR) at Week 24. Started Apr 2011; status: completed.
02
Drugs
cobicistat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-000488-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000488-29.